Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

While most of its current revenue comes from the contract manufacturing business, Samsung Biologics aims to increase its exposure in the contract development organization business, which provides a ...

Samsung Biologics has made history by becoming the nation's first biotech company to hit 4 trillion won ($2.78 billion) in ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Samsung Biologics achieved record annual revenue of 4.55 trillion won in 2024, with a 23 percent increase year over year.

That SPC is due to expire later this year. In anticipation of that, Samsung Bioepis is exploring the development of its own rival biosimilar to denosumab – biosimilars are medicines that are highly ...

The South Korean firm just agreed to buy Biogen out of their biosimilar joint venture – Samsung Bioepis – for $2.3 billion. The two companies have been partnered on Samsung Bioepis for the ...

Number 2: Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, ...

Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz. Byooviz (ranibizumab ...